WO2004031165A1 - 治療剤 - Google Patents
治療剤 Download PDFInfo
- Publication number
- WO2004031165A1 WO2004031165A1 PCT/JP2003/012381 JP0312381W WO2004031165A1 WO 2004031165 A1 WO2004031165 A1 WO 2004031165A1 JP 0312381 W JP0312381 W JP 0312381W WO 2004031165 A1 WO2004031165 A1 WO 2004031165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- production
- present
- active ingredient
- aldose reductase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Definitions
- the present invention relates to a novel chalcone compound, and a medicine, food and drink, etc., utilizing the physiological action of the compound.
- a chalcone compound is a general term for compounds having a chalcone skeleton represented by the following formula, and various compounds obtained by extraction or synthesis from natural products are known as these compounds.
- the biological activity of these compounds varies depending on the compound, such as cytotoxicity, anticancer activity, chemoprotection, antimutagenicity, antibacterial activity, antiviral activity, antiprotozoal activity, and insecticidal activity.
- cytotoxicity See, for example, JR Dim mock and 3 others, Currrent Medicine Chemistry, (Netherlands), 1999, Vol. 6, p. 1125-: L149).
- the present inventors have found that these chalcone compounds have an effect of enhancing the production of nerve growth factor (NGF) (see, for example, International Publication No. 0 154 628, Pan fret). . Disclosure of the invention
- An object of the present invention is to provide a novel chalcone compound and a drug, a food or drink, etc. utilizing the physiological action thereof.
- the present invention relates to a compound represented by the following general formula (1), a derivative thereof, or a salt thereof.
- R i and R 2 together with the carbon atoms to which they are attached each form a hydroxydimethylcyclohexane ring, or represents a hydroxyl group, in which case R 2 is Represents a hexenyl group.
- the second invention of the present invention relates to a therapeutic or prophylactic agent for a disease sensitive to the compound, comprising the compound of the first invention of the present invention as an active ingredient.
- the disease sensitive to the compound includes protection of nerve cells, suppression of nitric oxide (NO) production, inhibition of aldose reductase or Diseases requiring suppression of interleukin production are exemplified.
- a third invention of the present invention is a neuroprotective agent, a NO production inhibitor, an aldose reductase inhibitor or an intamine, comprising the compound of the first invention of the present invention as an active ingredient.
- a fourth invention of the present invention is characterized in that the compound of the first invention of the present invention is contained as an active ingredient, and it is characterized by protecting neurons, inhibiting NO production, inhibiting aldose reductase or inhibiting interleukin production.
- the present invention relates to a food, beverage or feed for the treatment or prevention of a disease requiring medical treatment.
- FIG. 1 is a diagram showing a mass spectrum of compound a.
- FIG. 2 is a diagram showing a 1 H-NMR spectrum of compound a.
- FIG. 3 is a view showing a 13 C-NMR spectrum of compound a.
- FIG. 4 is a diagram showing a mass spectrum of compound b.
- FIG. 5 is a chart showing a 1 H-NMR spectrum of the compound.
- FIG. 6 is a chart showing 13 C-NMR spectrum of the compound.
- FIG. 7 is a graph showing the inhibitory effect of compound a and compound b on NO production.
- FIG. 8 is a graph showing the inhibitory action of compound a and compound b on IL-6 production.
- the present inventors have proposed a novel chalcone compound derived from an edible plant represented by the above general formula (1), a derivative thereof or a salt thereof (hereinafter, sometimes referred to as the compound of the present invention); It has been found that it has a protective effect on nerve cells, an inhibitory action on NO production, an inhibitory action on aldose reductase and an inhibitory action on interleukin production, and it has become possible to provide drugs, foods and drinks and feeds containing the compound as an active ingredient.
- the compounds of the present invention are represented by the following formula (A) (-(5, 6, 7, 8, 8a, 10a-hexahydrol-1, 7-dihydroxy- 8, 8, 10a-trimethyl-9H-xanthen-4-yl) -3- (4-hydroxyphenyl) -2-propen-l-one and the compound (3,4, -dihydro- 3, 5-dihydroxy-2- (3_isohexeneyl) -2-methyl-2H-l-benzopyran-8-yl) -3- (4-hydroxyphenyl) -2-propene-l-one.
- the compound of the present invention used as an active ingredient in the present invention may be derived from a natural product, or may be a synthetic product or a semi-synthetic product.
- the natural product is preferably derived from an edible plant, and the edible plant is exemplified by Acertapa, an Apiaceae plant.
- Acertapa an Apiaceae plant.
- any of them can be arbitrarily used in the present invention.
- the compounds of the present invention can be used alone or as a mixture of two or more.
- the derivative of the compound represented by the general formula (1) is a compound synthesized using the compound as an original compound, and has the same action as the compound represented by the general formula (1) ′, That is, it is a compound having a neuroprotective action, a NO production inhibitory action, an aldose reductase inhibitory action or an interleukin production inhibitory action.
- compounds (prodrugs) which can be easily hydrolyzed in the body to exhibit a desired effect, such as ester, ether and glycoside of the compound represented by the above general formula (1), Can be mentioned. Preparation of such a prodrug may be performed according to a known method.
- such a derivative may be a salt thereof.
- pharmacologically acceptable salts are preferred.
- the salt used in the present invention include an alkali metal salt, an alkaline earth metal salt, and a salt with an organic base.
- pharmacologically acceptable salts are preferred.
- the pharmacologically acceptable salt used in the present invention means a salt which is substantially non-toxic to living organisms.
- Such salts include, for example, sodium, potassium, calcium, magnesium, ammonium or protonated benzathine (N, N'-di-benzylethylenediamine), choline, ethanolamine, diethanolamine, ethylenediamine, Examples include salts with megramin (N-methyldilucamine), benequinamine (N-benzylphenethylamine), piperazine or tromethamine (2-amino-12-hydroxymethyl-1,3-propanediol).
- the compound of the present invention derived from a natural product can be produced by a combination of known production methods.
- the compound can be purified from a compound containing the compound represented by the general formula (1), for example, a plant such as ash.
- Known purification means such as a chemical method and a physical method may be used as the purification means, such as a gel filtration method, a fractionation method using a molecular weight fractionation membrane, a solvent extraction method, and various types of chromatography using an ion exchange resin.
- the compound of the present invention may be purified by a combination of a conventionally known purification method such as a method.
- the compound of the present invention can be produced by referring to Examples 1 and 2 below.
- a semi-synthetic product can be obtained by organic synthesis using a chalcone compound derived from a natural product as a raw material, A synthetic product is obtained by organic synthesis of all.
- the method of organic synthesis is described in, for example, Alessandra Lat anz iet al., Synl et t. 2002, No. 6, P942-946; L. Claisen A. et a Ber. 1881, No. 14, p2460. Please refer to the following.
- a therapeutic or prophylactic agent for a disease showing sensitivity to the compound comprising the compound of the present invention as an active ingredient.
- the disease showing sensitivity to the compound refers to a disease in which a therapeutic or preventive effect can be obtained by the compound.
- the disease include protection of nerve cells, suppression of NO production, inhibition of aldose reductase. Or a disease requiring suppression of interleukin production.
- Brain dysfunction associated with neuronal cell death has been identified as a major cause of many central degenerative diseases such as stroke, senile dementia, Alfachima's disease, Huntington's disease, Parkinson's disease, and cerebral ischemia. Grayed Le evening Min acid as the mechanism of neuronal cell death observed in these diseases - C a 2 + _ N_ ⁇ theory has been proposed, with the role of NO as Medeie Isseki one nerve cell death is noted I have.
- the compound of the present invention has a protective action on neurons from NO donors (a suppressive action on NO toxicity), and is therefore a useful compound for diseases requiring neuronal protection.
- the diseases requiring neuronal protection include, for example, stroke, senile dementia, Alzheimer's disease, Huntington's disease, Parkinson's disease, cerebral ischemia and the like. Patients are exemplified.
- vascular endothelial growth factor and vascular permeability factor play an important role in this process.
- VEGF is induced by NO in various cancer cells. That is, by suppressing NO production of cancer cells, VEGF production is suppressed, and as a result, angiogenesis around cancer tissues is inhibited, and cancer can be dropped.
- NO reacts with amine under physiological conditions of neutral pH to produce nitrosamine.
- This nitrosamine is known to be carcinogenic by damaging DNA.
- NO production is increased in patients with liver fluke infection and cirrhosis, which are epidemiologically highly associated with cancer. Therefore, suppressing NO production can prevent carcinogenesis in high-risk groups.
- NO also induces the edema characteristic of inflammatory lesions, ie, a vascular hyperpermeability effect [Jap anese Journal of Cancer Research, Vol. 85, pp. 331-334 (1994). In addition, it enhances the biosynthesis of prostaglandins, which are all inflammatory mediators [Proceedings of National Acid Admi cof Sciences of USA, Vol. 90, pp. 7240-7244 (1993)].
- NO reacts quickly with superoxide radicals to generate peroxynitrite, which is also thought to cause inflammatory cell and tissue damage.
- synovial fluid in the affected area of patients with arthritis such as rheumatoid arthritis, rheumatoid arthritis, gouty arthritis, and Peet's disease has a higher concentration than that of the normal joints of the patient and the joints of healthy subjects. NO is included.
- the compound of the present invention is a compound useful for the above-mentioned cancerous diseases and inflammatory diseases because it has an N ⁇ production inhibitory action.
- Diseases that require effective inhibition of NO production by the compounds of the present invention include, for example, cancerous diseases, inflammatory diseases Disease, rheumatoid arthritis, rheumatoid arthritis, gouty arthritis, Behcet's disease and the like.
- Aldose reductase (Aldose red u ct a se: hereinafter may be referred to as AR) is an enzyme involved in the polyol pathway which is one of glucose metabolism pathways in a living body.
- the pathway is composed of a glucose-sorbitol-based reduction pathway involving AR and a dehydrogenation reaction pathway from sorbitol to D-fructose involving sorbitol dehydrogenase (hereinafter sometimes referred to as SDH).
- SDH dehydrogenation reaction pathway from sorbitol to D-fructose involving sorbitol dehydrogenase
- the SDH activity is lower than the AR activity, the continued influx of dalcose produces a large amount of the intermediate metabolite sorbitol.
- Various diseases caused by the accumulation of sorbitol that is, diseases that occur as diabetic complications include, for example, cataracts, peripheral nerve diseases, renal diseases, infectious diseases caused by reduced phagocytosis of leukocytes, and diabetic.
- Coma and arteriosclerosis due to atherosclerosis in the large vessel wall are known diseases.
- the compound of the present invention has an AR inhibitory effect and is therefore useful for the above-mentioned diabetic complications.
- Examples of the disease in which the compound of the present invention requires an effective AR inhibitory effect include, for example, diseases caused as diabetic complications, such as cataracts, peripheral nerve diseases, renal diseases, infectious diseases caused by reduced phagocytosis of leukocytes, and diabetes. Diseases such as sexual coma, arteriosclerosis due to atherosclerosis in the large blood vessel wall are exemplified.
- the compounds of the present invention can also be used in combination with other therapeutic agents for diabetes.
- Interleukin is a generic term for proteinaceous physiologically active substances produced by lymphocytes, monocytes, etc., and the existence of interleukins 1-25 is known.
- Inter-kinin-6 (hereinafter sometimes referred to as IL-6) is a factor that induces the terminal differentiation of B cells, and is responsible not only for immune responses but also for cell differentiation and acute reactions of hematopoietic and nervous systems. Is involved in the development of various immune disorders, inflammatory diseases, and lymphoid tumors. Are also closely related.
- IL-16 induces antibody production on B cells and produces IgM, IgG, and IgA classes of immunoglobulins, but unlike IL-4, it is involved in class switches. do not do.
- IL-6 also acts as a growth factor for B cells and plasma sites. On the other hand, it is also involved in the T cell system, and proliferates and differentiates T cells. IL-16 is also involved in the hematopoietic system and works with IL-13 to proliferate hematopoietic stem cells by shortening the GO phase. It also promotes megakaryocyte maturation and induces an increase in platelets. IL-16 is also involved in the acute phase response of living organisms, such as bacterial and viral infections and malignant tumors. IL-6 is also involved in the nervous system, is secreted from nervous system cells such as Darioblast-Mastastoma, and also works to induce nervous system differentiation.
- B cells are activated in rheumatoid arthritis and systemic lupus erythematosus, and it is known that IL-16 is present in high concentrations in the synovial fluid of patients.
- Castleman syndrome which is characterized by systemic lymphadenopathy, it is known that the blood IL-16 level is extremely high.
- IL-16 is likely to be a self-growth factor for myeloma cells, because the proliferation of myeloma cells derived from multiple myeloma patients is suppressed by anti-IL-16 antibody.
- urine from patients with primary glomerulonephritis also contains IL-6, and it is known that IL-16 acts as a growth factor for renal mesangial cells.
- the compound of the present invention has an inhibitory effect on IL-16 production, and is therefore a useful compound for diseases requiring suppression of IL-16 production.
- Diseases in which the compound of the present invention is effective and require suppression of IL-16 production include, for example, rheumatoid arthritis, systemic lupus erythematosus, B-cell dysfunction, Castleman syndrome, autoimmune disease, atrial myxoma, multiple occurrences Diseases such as primary myeloma, primary glomerulonephritis, mesangial cell proliferative glomerulonephritis, plasmacytoma, myeloma, and acquired immunodeficiency (AIDS) Is shown.
- AIDS acquired immunodeficiency
- the above-described therapeutic or prophylactic agent of the present invention can be produced by formulating the compound of the present invention as an active ingredient and combining it with a known pharmaceutical carrier.
- these compounds are formulated with a pharmaceutically acceptable liquid or solid carrier and, if necessary, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, By adding a disintegrant, a lubricant and the like, solid preparations such as tablets, granules, powders, powders and capsules, and liquid preparations such as ordinary liquid preparations, suspensions and emulsions can be prepared.
- a dried product which can be made into a liquid form by adding an appropriate carrier before use can be obtained.
- the pharmaceutical carrier can be selected according to the administration form and dosage form of the therapeutic or prophylactic agent.
- an oral preparation comprising a solid composition
- tablets, pills, capsules, powders, fine granules, granules and the like can be used.
- starch, lactose, sucrose, mannitol, carboxymethylcellulose, Corn starch and inorganic salts are used.
- a binder, a disintegrant, a surfactant, a lubricant, a fluidity promoter, a flavoring agent, a coloring agent, a fragrance, and the like can be further blended.
- tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, or a film of a gastric or enteric substance, if desired.
- a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, or a film of a gastric or enteric substance
- an oral preparation comprising a liquid composition
- it can be a pharmacologically acceptable emulsion, solution, suspension, syrup, etc.
- purified water, ethanol, etc. are used as carriers Is done.
- auxiliary agents such as wetting agents and suspending agents, sweetening agents, flavoring agents, preservatives and the like may be added.
- a parenteral preparation when used, distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, and the like, as the diluent, the active ingredient of the present invention in a usual manner. It can be prepared by dissolving or suspending in corn oil, propylene glycol, polyethylene glycol, or the like, and adding a bactericide, a stabilizer, an isotonic agent, a soothing agent, and the like, if necessary. In addition, a solid composition can be prepared and dissolved in sterile water or a sterile solvent for injection before use.
- External preparations include solid, semi-solid or liquid preparations for transdermal administration or transmucosal (oral, nasal) administration. Suppositories are also included.
- emulsion preparations such as emulsions and lotions
- liquid preparations such as tinctures for external use
- liquid preparations for transmucosal administration ointments
- ointments such as oily ointments and hydrophilic ointments
- transdermal preparations such as films, tapes and cataplasms It can be a patch for administration or transmucosal administration.
- each of the above-mentioned various preparations can be appropriately produced by a conventional method using a known pharmaceutical carrier or the like.
- the content of the active ingredient in such a preparation is not particularly limited as long as the active ingredient can be administered in the dosage range described below, preferably in consideration of the dosage form, administration method, and the like. is not.
- the content of the active ingredient in the therapeutic or prophylactic agent of the present invention is not particularly limited, but is usually 0.001 to 80% by weight, preferably 0.01 to 50% by weight, and particularly preferably 0.1-20% by weight is exemplified.
- the dose of the therapeutic or prophylactic agent of the present invention is appropriately determined depending on the form, administration method, purpose of use, and the age, weight, and symptoms of the patient to which it is applied, and is not fixed.
- the amount of the active ingredient contained is 10 ⁇ g to lg / kg body weight, preferably 50 g to 500 mg / kg body weight, and more preferably 100 g to 100 mg / kg body weight per day for humans (for example, adults).
- a dose smaller than the above-mentioned dose may be sufficient, or may be required beyond the range.
- the drug of the present invention can be administered orally as it is, or can be added to any food or drink for daily ingestion.
- a neuroprotective agent, a NO production inhibitor, an aldose reductase inhibitor or an interleukin production inhibitor containing the compound of the present invention as an active ingredient can be provided.
- the nerve cell protective agent, NO production inhibitor, aldose reductase inhibitor or interleukin production inhibitor of the present invention may be the active ingredient itself, or a composition containing the active ingredient. Is also good.
- a pharmacologically acceptable salt is preferably used as the active ingredient.
- the nerve cell protective agent, NO production inhibitor, aldose reductase inhibitor or inhaled leukin production inhibitor of the present invention includes, for example, other components which can be used for the same active ingredient as the active ingredient.
- the content of the active ingredient in the nerve cell protective agent, the N ⁇ production inhibitor, the aldose reductase inhibitor or the interleukin production inhibitor of the present invention is determined by considering the administration method, intended use, and the like of the present invention.
- the amount is not particularly limited as long as the desired effect can be obtained, and is usually, but not limited to, 0.001 to 100% by weight, preferably 0.01 to 80% by weight. % By weight, particularly preferably 0.1 to 80% by weight.
- the amount used is not particularly limited as long as the desired effects of the present invention can be obtained.
- the nerve cell protective agent, NO production inhibitor, aldose reductase inhibitor or interleukin production inhibitor of the present invention requires nerve cell protection, NO production inhibition, aldose reductase inhibition or interleukin production inhibition. Useful in diseases.
- the neuroprotective agent, NO production inhibitor, aldose reductase inhibitor or interleukin production inhibitor of the present invention is also useful for screening drugs for these diseases. Further, the nerve cell protective agent, NO production inhibitor, aldose reductase inhibitor or interleukin production inhibitor of the present invention is also useful for functional studies on physical changes in these diseases.
- the food or drink or feed of the present invention contains the active ingredient. That is, a food, beverage or feed containing, added or Z- or diluted with the compound of the present invention, which has a neuroprotective effect, NO production inhibitory effect, aldose reductase inhibitory effect or interleukin production inhibitory effect. It is extremely useful for ameliorating and preventing the symptoms of diseases that require protection of nerve cells, suppression of N ⁇ production, inhibition of aldose reductase, or suppression of interleukin production.
- the term "containing” refers to a mode in which the active ingredient used in the present invention is contained in a food, beverage, or feed
- addition refers to a raw material of a food, beverage, or feed.
- the term “dilution” refers to a mode in which a food, beverage or feed material is added to the active ingredient used in the present invention. is there.
- the method for producing the food, beverage or feed of the present invention is not particularly limited, and a generally used method for producing food, beverage or feed can be adopted. It is only necessary that the compound be contained as a high content of the active ingredient.
- the high content means that the weight of the compound of the present invention per unit weight of the food, beverage or feed of the present invention is more than the weight of the compound of the present invention per unit weight of the raw material, for example, acitapa. It means more.
- the food or beverage of the present invention is not particularly limited, for example, processed cereals, processed fats and oils, processed soybeans, processed meats, marine products, dairy products, processed vegetables and fruits, confectionery, alcohol Foods, flavored drinks, seasonings, canned bottled food, semi-dried or concentrated food, dried food, frozen food, solid food, liquid food, spices, etc. Processed marine products and the like.
- the food or beverage of the present invention contains one or more of the above-mentioned active ingredients, is added and Z- or is diluted, and has a neuroprotective effect, an NO production inhibitory effect, an aldo-reductase inhibitory effect or an interleukin production inhibitory effect.
- the form is not particularly limited as long as it contains a necessary amount for exhibiting the action, and includes an orally ingestible form such as a tablet, a granule, and a capsule.
- the content of the active ingredient in the food or beverage of the present invention is not particularly limited, and can be appropriately selected from the viewpoints of its functionality and activity.
- 100% by weight of food preferably 0.0000. 1% by weight or more, more preferably 0.001 to: 0% by weight of L, more preferably 0.006 to 6% by weight, for example, in beverages of 100% by weight, It is preferably 0.0001% by weight or more, more preferably 0.0001 to 10% by weight, and even more preferably 0.0006 to 6% by weight.
- the food or beverage of the present invention preferably contains an active ingredient contained therein in an amount of 10 g to lg / kg body weight, preferably 50 g to 50 OmgZkg body weight per day for humans (for example, adults). Or 100 g to 10 Omg / kg body weight.
- the present invention provides a feed for living organisms having the nerve cell protective action, NO production inhibitory action, aldose reductase inhibitory action, or quinone lipequine production inhibitory action, comprising the active ingredient.
- the present invention provides a method for breeding an organism, which comprises administering the active ingredient to the organism.
- an agent for raising a living organism comprising the active ingredient.
- “containing” means the above-mentioned content, addition and Z or dilution.
- the organisms are, for example, farm animals, pet animals, and the like, and the farm animals include livestock, laboratory animals, poultry, fish, crustaceans, and shellfish.
- the feed include a feed for maintaining and / or improving physical condition.
- the breeding agent include an immersion agent, a feed additive, and a beverage additive.
- the active ingredient used in the present invention has a neuronal cell protecting effect, a NO production suppressing effect, an aldose reductase inhibitory effect or an interleukin production suppressing effect. Based on the action, it is expected that the same effect as that of the therapeutic or prophylactic agent of the present invention will be exhibited. That is, the feed and the breeding agent for living organisms of the present invention have a therapeutic or preventive effect on diseases requiring neuronal cell protection, NO production suppression, aldose reductase inhibition or interleukin production suppression in the organism to which they are applied. Having.
- the effective ingredient used in the present invention is usually 1 day 10 ⁇ ⁇ 1 gZkg weight to the subject organism, preferably 50 g ⁇ 500mg / kg body weight, more preferably 1 00 X g ⁇ l 0 OmgZk g body weight administered .
- Administration may be, for example, Can be added to and mixed with the raw material of the artificial mixed feed to be provided to the target organism, or mixed with the powdered raw material of the artificial mixed feed and then further added to and mixed with other raw materials.
- the content of the active ingredient in the feed is not particularly limited,
- the method for producing the feed of the present invention is not particularly limited, and the composition may be the same as that of a general feed.
- the active ingredient of the present invention having an interleukin production inhibitory action may be contained.
- the agent for breeding organisms may be produced, used, etc. according to the feed.
- the organisms to which the present invention can be applied are not limited, but the cultured animals include livestock such as horses, sea lions, pigs, sheep, goats, camels, and llamas, and experimental animals such as mice, rats, guinea pigs, and egrets. Poultry such as chickens, chickens, ducks, turkeys and ostriches, and pet animals such as dogs and cats are widely applicable.
- Livestock, experimental animals, poultry, pet animals can be obtained by immersing the target organism in a solution containing the active ingredient used in the present invention, which has a production inhibitory action, an inhibitory action on aldose reductase or an inhibitory action on interleukin production. You can maintain or improve your physical condition.
- the embodiment exemplified here forms one embodiment of the method for breeding an organism provided by the present invention.
- the content of the compound of the present invention in pharmaceuticals, foods and drinks, and feeds may be a concentration at which a desired effect can be obtained in a living body by administration, ingestion, and the like. It is desirable that the content be higher than the content of the compound of the present invention.
- the compound of the present invention or a salt thereof used in the present invention is toxic when administered orally to mice. No gender is observed.
- Example 1 (£)-1- (5, 6, 7, 8, 8a, lOa-hexahydro-1, 7-dihydroxy-8, 8, 10a-trimethy l-9H-xanthen-4-yl) -3- Preparation of (4-hydroxyphenyl) _2-propen-1-one
- Example 1 After concentrating 5 Om1 of the fraction eluted in the 50% ethanol aqueous solution of (4) in the first elution fraction under reduced pressure, dissolve it in 3 ml of 50% ethanol aqueous solution, and use reverse phase chromatography. And fractionated. The conditions are described below.
- the column used was TSK gel ODS-80 Ts (21.5 mm X 30 cm: manufactured by Tosoh Corporation).
- the solvent used was a mixture of distilled water and acetonitrile at a volume ratio of 1: 1.
- the elution rate was 5 m 1 Zmin and the detection was at 215 nm.
- Reversed-phase chromatographic fractions 1 to 5 were collected using the ultraviolet absorption of the eluate as an index.
- the mass spectrum (MS) of the fraction containing the 1-minute detection peak) was measured by a FAB-MS method using a mass spectrometer (DX 302: manufactured by JEOL Ltd.).
- the matrix used was m-nitrobenzyl alcohol. As a result, m / z 407
- FIG. 2 shows the 1 H-NMR spectrum.
- the horizontal axis represents the chemical shift value
- the vertical axis represents the signal intensity.
- FIG. 3 shows the 13 C-NMR spectrum.
- the horizontal axis indicates the chemical shift value
- the vertical axis indicates the signal intensity.
- the reversed-phase chromatofraction 2 was (£) -total (5, 6, 7, 8, 8a, 10a-hexa hydro-1 7-dihydroxy-8, 8, 1 Oa- 1 ri me t hy 1 -9H-x anth hen-4-y 1) -3- (4-hyd r oxypheny l) -2-propen-l-one ( The molecular weight was 408, and it was determined to be Compound a) below.
- Example 1-1 The mass spectrum of the reversed-phase chromatographic fraction 4 (fraction containing the detection peak at a retention time of 36.2 minutes) obtained in Example 1-1 (5) was measured in the same manner as in Example 1 _ (6). did.
- the matrix used was m-nitrobenzyl alcohol.
- Figure 4 shows the mass spectrum of reversed-phase chromatographic fraction 4. In FIG. 4, the horizontal axis represents the mZz value, and the vertical axis represents the relative intensity.
- the NMR spectrum of the reversed-phase chromatographic fraction 4 was measured in the same manner as in Example 11- (6).
- the NMR assignment signals are shown below.
- the peak assignment numbers are shown in the following formula (D).
- FIG. 5 shows the 1 H-NMR spectrum of the reversed-phase chromatographic fraction 4.
- the horizontal axis represents the chemical shift value
- the vertical axis represents the signal intensity.
- FIG. 6 shows the 13 C-NMR spectrum of reversed-phase chromatographic fraction 4.
- the horizontal axis represents the chemical shift value
- the vertical axis represents the signal intensity.
- the aldose reductase inhibitory activity of compounds a and b was measured by the following method.
- Compound a or b as sample dissolved in 50% aqueous dimethyl sulfoxide solution) 10 1, 0.2M phosphate buffer (pH 6.2) 100 and IraM NADPH (phosphate buffer) 20
- Aldose reductase solution 0.1 UZm1, phosphate buffer solution, manufactured by Wako Pure Chemical Industries, Ltd.
- 10 1 0.1 UZm1, phosphate buffer solution, manufactured by Wako Pure Chemical Industries, Ltd.
- NADPH is added for 180 seconds.
- the change in absorbance at 340 nm was measured.
- As a negative control a 50% dimethyl sulfoxide aqueous solution was used instead of the sample.
- the absorbance was measured using distilled water as a blank for each sample instead of methyldalioxal solution. The measured value was shown as the average of two experimental values.
- Inhibition rate (%) [1-[(AAs-AAsb) / (AAc-AAcb)]]
- AAs and AAc represent the absorbance changes per minute of the sample solution and the negative control solution, respectively
- AAsb and AAcb represent the absorbance changes per minute of the sample solution and the negative control solution, respectively.
- the NO toxicity inhibitory activity of compound b was measured by the following method. Rat adrenal medulla brown cell-derived PC12 cells (CRL_1721) were suspended in 1 x 10 5 cells Zml in DMEM medium (BioWita) containing 10% fetal serum (Biowita) and placed in a 96-well plate. 0.1 ml was sown and cultured at 37 ° C in the presence of 5% carbon dioxide. After culturing for 24 hours, the medium was removed, and replaced with 10 ngZml of NGF (manufactured by Takara Bio Inc.) and DMEM medium containing 10% fetal serum, and cultured for 3 days to differentiate PC12 cells into neurons. .
- NGF manufactured by Takara Bio Inc.
- the cell viability () was calculated from the MTT measurement value of each test group, with the MTT measurement value of the control group (containing no compound b or SNP) being 100. As a result, it was revealed that compound b has an inhibitory activity on cytotoxicity induced by SNP. Table 2 shows the results. Table 2
- the NO toxicity inhibitory activity of compound b was measured by the following method. Rat adrenal PC12 cells derived from medullary brown cells are suspended in 1.5 x 10 5 cells Zm1 in DMEM medium containing 10% fetal calf serum, and 0.1 ml is spread on a 96-well plate in the presence of 5% carbon dioxide. , 37. After culturing for 24 hours, the medium was removed, and the cells were replaced with the compound b of 10] ⁇ and DMEM medium containing 10% fetal calf serum. After culturing for 2 hours, SNP was added to 50 and cultured for 66 hours. After completion of the culture, MTT was measured in the same manner as in Example 4 (1), and the cell viability (%) was calculated. All measurements were performed in triplicate. As a result, it was revealed that compound b had an inhibitory activity on cytotoxicity induced by SNP. Table 3 shows the results. Table 3
- RAW264.7 cells ATCC TIB
- Dulbecco's modified Eagle's medium Bayouita, 12-604F
- 10% fetal serum Gibco
- Compound b (dimethyl sulfoxide solution) was added so as to have a concentration of 12, 24 M. After further culturing for 1 hour, add 51 ⁇ l of an aqueous solution of 100 g / m1 lipopolysaccharide (LPS, Sigma, L-2010) to each well and incubate for 15 hours. The measurement of the N 2 -concentration caused by oxidation in the medium was performed. As a positive control, a category without addition of compounds a and b was set, and as a negative control, a category without addition of LPS was set.
- LPS lipopolysaccharide
- FIG. 7 shows the results. That is, FIG. 7 is a diagram showing the concentration of N 2 — in the medium. In Figure 7, the horizontal axis represents the samples, and the vertical axis N0 2 - indicates the concentration (M).
- Example 6 Inhibitory activity of compound a and compound b on IL-16 production
- RAW264.7 cells ATCC TIB
- Dulbecco's Modified Eagle Medium Piowita, 12-604F
- 10% fetal serum Gibco
- aqueous solution of 51 100 g / m1 lipopolysaccharide (LPS, Sigma, L-2010) was added to each well, followed by culturing for 15 hours. Collected. The content of interleukin 6 (IL-6) in the culture supernatant was measured using Enzymimno Sandwich Atssey (Genzyme Techne, 4922). As a positive control, a category without addition of compounds a and b was set, and as a negative control, a category without addition of LPS was set. All measurements were performed in duplicate.
- FIG. 8 is a graph showing the concentration of IL-6 (pg / ml) in the culture supernatant.
- the horizontal axis represents each sample, and the vertical axis represents the IL-16 concentration (pg / ml).
- a novel chalcone compound is provided.
- the compound has a neuroprotective effect, a NO production inhibitory effect, an aldose reductase inhibitory effect, or an inulin-leukin production inhibitory effect, and is effective for pharmaceuticals, foods, drinks or feeds utilizing the physiological activity. Useful as an ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003272901A AU2003272901A1 (en) | 2002-10-01 | 2003-09-29 | Remedies |
JP2004541240A JPWO2004031165A1 (ja) | 2002-10-01 | 2003-09-29 | 治療剤 |
CA002501017A CA2501017A1 (en) | 2002-10-01 | 2003-09-29 | Remedies |
EP03753963A EP1574506A4 (en) | 2002-10-01 | 2003-09-29 | REMEDIES |
US10/529,859 US7361774B2 (en) | 2002-10-01 | 2003-09-29 | Chalcone compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-289050 | 2002-10-01 | ||
JP2002289050 | 2002-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004031165A1 true WO2004031165A1 (ja) | 2004-04-15 |
Family
ID=32063703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/012381 WO2004031165A1 (ja) | 2002-10-01 | 2003-09-29 | 治療剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7361774B2 (ja) |
EP (1) | EP1574506A4 (ja) |
JP (1) | JPWO2004031165A1 (ja) |
KR (1) | KR20050053731A (ja) |
CN (1) | CN100506813C (ja) |
AU (1) | AU2003272901A1 (ja) |
CA (1) | CA2501017A1 (ja) |
TW (1) | TW200501944A (ja) |
WO (1) | WO2004031165A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100336797C (zh) * | 2005-08-19 | 2007-09-12 | 浙江大学 | 四取代查耳酮衍生物及制备方法和用途 |
US10071945B2 (en) | 2011-06-15 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1563841A4 (en) * | 2002-10-01 | 2009-08-12 | Takara Bio Inc | REMEDIES |
JP2006137747A (ja) * | 2004-10-14 | 2006-06-01 | Hayashibara Biochem Lab Inc | サイトカイン類及び/又はケモカイン類産生増強剤 |
WO2008016738A2 (en) * | 2006-05-18 | 2008-02-07 | Wisconsin Alumni Research Foundation | Antibacterial agents and related screening methods using small molecule macroarrays |
CN101058558B (zh) * | 2007-05-28 | 2013-04-10 | 沈阳药科大学 | 具有醛糖还原酶抑制活性的4-氧代-1(4h)-喹啉羧酸类化合物、组合物及其制备方法 |
JP2009171949A (ja) * | 2007-07-18 | 2009-08-06 | Takara Bio Inc | 明日葉茶 |
CN101759543B (zh) * | 2009-12-31 | 2013-04-10 | 青岛海隆达生物科技有限公司 | 从新鲜明日叶中提取查尔酮的方法 |
CN116023247A (zh) * | 2021-10-27 | 2023-04-28 | 暨南大学 | 2-丙烯-1酮类化合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63104912A (ja) * | 1986-10-21 | 1988-05-10 | Tsumura & Co | アルド−スリダクタ−ゼ阻害剤 |
JPH07165588A (ja) * | 1993-12-13 | 1995-06-27 | Tsumura & Co | 脳機能改善剤 |
JP2000072766A (ja) * | 1998-08-27 | 2000-03-07 | Dai Ichi Seiyaku Co Ltd | ベンゾピラン誘導体 |
JP2001058969A (ja) * | 1999-08-20 | 2001-03-06 | Nettairin Saisei Gijutsu Kenkyu Kumiai | 一酸化窒素産生抑制剤 |
WO2002049632A1 (fr) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibiteurs de production et de liberation de cytokines inflammatoires |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02231057A (ja) * | 1989-03-03 | 1990-09-13 | Sanmi Shoji Kk | あしたば粉末の製造方法 |
JPH0823912A (ja) * | 1994-07-19 | 1996-01-30 | Yoshinobu Umeda | アシタバ入り食品 |
EP1254658B1 (en) | 2000-01-27 | 2008-09-24 | Takara Bio Inc. | Remedies for the treatment of nerve diorders |
AU2001246876A1 (en) * | 2000-04-10 | 2001-10-23 | Takara Bio Inc. | Remedies |
AU2001246877A1 (en) * | 2000-04-11 | 2001-10-23 | Takara Bio Inc. | Remedies |
JP4986320B2 (ja) * | 2000-10-05 | 2012-07-25 | レックテックラボラトリーズ株式会社 | カルコン含有粉末組成物 |
EP1563841A4 (en) * | 2002-10-01 | 2009-08-12 | Takara Bio Inc | REMEDIES |
-
2003
- 2003-09-29 WO PCT/JP2003/012381 patent/WO2004031165A1/ja active Application Filing
- 2003-09-29 KR KR1020057005758A patent/KR20050053731A/ko not_active Application Discontinuation
- 2003-09-29 CA CA002501017A patent/CA2501017A1/en not_active Abandoned
- 2003-09-29 US US10/529,859 patent/US7361774B2/en not_active Expired - Fee Related
- 2003-09-29 JP JP2004541240A patent/JPWO2004031165A1/ja active Pending
- 2003-09-29 CN CNB038236281A patent/CN100506813C/zh not_active Expired - Fee Related
- 2003-09-29 EP EP03753963A patent/EP1574506A4/en not_active Withdrawn
- 2003-09-29 AU AU2003272901A patent/AU2003272901A1/en not_active Abandoned
- 2003-10-01 TW TW092127190A patent/TW200501944A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63104912A (ja) * | 1986-10-21 | 1988-05-10 | Tsumura & Co | アルド−スリダクタ−ゼ阻害剤 |
JPH07165588A (ja) * | 1993-12-13 | 1995-06-27 | Tsumura & Co | 脳機能改善剤 |
JP2000072766A (ja) * | 1998-08-27 | 2000-03-07 | Dai Ichi Seiyaku Co Ltd | ベンゾピラン誘導体 |
JP2001058969A (ja) * | 1999-08-20 | 2001-03-06 | Nettairin Saisei Gijutsu Kenkyu Kumiai | 一酸化窒素産生抑制剤 |
WO2002049632A1 (fr) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibiteurs de production et de liberation de cytokines inflammatoires |
Non-Patent Citations (3)
Title |
---|
PARMAR, V.C. ET AL: "Anti-invasive Activity of Alkaloids and Polyphenolics in Vitro", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 5, no. 8, 1997, pages 1609 - 1619, XP000226722 * |
See also references of EP1574506A4 * |
YOOK, C-H ET AL: "Alkylation of Orcinol with Nerol in Modified lewis Acid.", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 13, no. 5, 1992, pages 457 - 458, XP002974946 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100336797C (zh) * | 2005-08-19 | 2007-09-12 | 浙江大学 | 四取代查耳酮衍生物及制备方法和用途 |
US10071945B2 (en) | 2011-06-15 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
US10737995B2 (en) | 2011-06-15 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
Also Published As
Publication number | Publication date |
---|---|
US20050272809A1 (en) | 2005-12-08 |
TW200501944A (en) | 2005-01-16 |
AU2003272901A1 (en) | 2004-04-23 |
CN1688566A (zh) | 2005-10-26 |
CN100506813C (zh) | 2009-07-01 |
EP1574506A4 (en) | 2007-05-30 |
KR20050053731A (ko) | 2005-06-08 |
CA2501017A1 (en) | 2004-04-15 |
EP1574506A1 (en) | 2005-09-14 |
JPWO2004031165A1 (ja) | 2006-02-02 |
US7361774B2 (en) | 2008-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2523946B1 (en) | Tricyclic sesquiterpene lactones for used in the treatment of obesity and related diseases and non-therapeutic treatable conditions | |
EP2438923B1 (en) | Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients | |
EP1623704A1 (en) | Therapeutic agent | |
JP5528025B2 (ja) | Tg合成抑制剤 | |
WO2004031165A1 (ja) | 治療剤 | |
KR20110120153A (ko) | 리모넨을 함유하는 아데노신 A2a 수용체 작용제 | |
JPWO2005074906A1 (ja) | 治療剤 | |
WO2012008467A1 (ja) | axial-equatorial aryl配向のfurofuran型リグナンを含有する骨形成促進用医薬組成物、その組成物を含有する医薬製剤、その組成物を含む機能性食品及び健康食品 | |
US20060100274A1 (en) | Therapeutic avenanthramide compounds | |
JPWO2006082743A1 (ja) | 治療剤 | |
WO2023199967A1 (ja) | eNAMPT増加剤、サーチュイン活性化又は発現増強剤、NAD+増加剤、及び老化細胞抑制剤 | |
TW200823219A (en) | ACAT inhibitor | |
US7498357B2 (en) | Chalcone compounds | |
JP2007186515A (ja) | 治療剤 | |
KR101794924B1 (ko) | 퉁퉁마디 유래 비알코올성 지방간 질환 예방 또는 치료용 이소람네틴의 분리방법 | |
KR101132174B1 (ko) | 에리스리나 아비시니카로부터 얻은 에이엠피케이를 활성화시키는 화합물 및 이를 유효성분으로 포함하는 대사증후군 관련 질환의 예방 또는 치료용 조성물 | |
JP2019163234A (ja) | キサンチンオキシダーゼ阻害剤及びその製造方法 | |
WO2004009521A1 (ja) | 治療剤 | |
KR20180088606A (ko) | 비알코올성 지방간 질환 예방 또는 치료능이 있는 이소람네틴(isorhamnetin)을 함유하는 퉁퉁마디(Salicornia SPP.) 물 추출물의 에틸아세테이트 분획물 | |
WO2014156462A1 (ja) | 白色脂肪細胞の褐色様脂肪細胞分化誘導剤 | |
JP2007131637A (ja) | 治療剤 | |
KR20240072608A (ko) | 워터코인 추출물 또는 이의 분획물을 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
KR20220170522A (ko) | 로리올라이드를 유효성분으로 포함하는 항염증용 조성물 | |
JP2023038107A (ja) | 脂質合成抑制剤及びこれを含む飲食品、脂質合成抑制用加工食品並びに発現抑制剤 | |
WO2003073870A1 (fr) | Aliments dietetiques ayant un effet anti-allergique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004541240 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2501017 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10529859 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057005758 Country of ref document: KR Ref document number: 20038236281 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003753963 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057005758 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003753963 Country of ref document: EP |